![Seth Harmon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 138 317 $ in data 31/05/2026
Seth Harmon is currently Chief Financial & Accounting Officer at Viridian Therapeutics, Inc. since 2023.
Formerly, Mr. Harmon was Chief Financial Officer at BioNTech SE from 2020 to 2023 and Vice President-Finance at BioNTech US, Inc. from 2017 to 2020.
Mr. Harmon completed undergraduate studies at Bowdoin College and earned graduate degrees, including an MBA, from Northeastern University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 7.850 ( 0,01% ) | 138 317 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Direttore Finanziario/CFO | 12/09/2023 |
| Società | Posizione | Fine |
|---|---|---|
| BIONTECH SE | Direttore Finanziario/CFO | 01/05/2023 |
| NEON THERAPEUTICS, INC. | Corporate Officer/Principal | 01/05/2020 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Bowdoin College
 Bowdoin College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNTech SE
 BioNTech SE BiotechnologyHealth Technology Develops immunotherapies and mRNA-based vaccines to treat cancer & infectious diseases | Health Technology |
BioNTech US, Inc.
 BioNTech US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immunotherapies for cancer | Health Technology |
Viridian Therapeutics, Inc.
 Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
